Andembry
(Garadacimab)ApprovedMonoclonal antibody
CSL BehringThis medication is a monoclonal antibody used to prevent attacks of hereditary angioedema, a genetic condition that causes recurring episodes of painful swelling in various parts of the body including the face, limbs, airway, and digestive tract. It works by blocking certain substances in the body that trigger angioedema symptoms.[2] Andembry is currently approved and in use across 2 indications[4].[1]
Andembry is one of 73 small molecule programs targeting Hereditary Angioedema. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
72
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
179 competitors in Idiopathic Pulmonary Fibrosis
#DrugCompanyPhaseTrials
1Thalomid
Bristol-Myers SquibbPhase 3
Tracleer
Johnson & JohnsonPhase 3
Prevacid
TakedaPhase 3
Letairis
GileadPhase 3
Gleevec
NovartisPhase 3
MS Contin
Merck & Co.Phase 3
Coumadin
AAbbott
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Jascayd
Boehringer IngelheimPhase 3
Bactrim
UUniversity of California, San Francisco
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[5]
Jun 16, 2025
ANDEMBRY
BLA BLA761367
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Andembry drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Garadacimab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[3]
- Highest Phase
- Approved[1]
- Company